MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- SUN PHARMA - MYLAN (US)
SUN PHARMA vs MYLAN (US) - Comparison Results
SUN PHARMA Change
Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 SUN PHARMA  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| SUN PHARMA Mar-20 |
MYLAN Dec-18 |
SUN PHARMA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 484 | 3,554 | - | |
| Low | Rs | 315 | 1,956 | - | |
| Sales per share (Unadj.) | Rs | 136.9 | 1,635.5 | - | |
| Earnings per share (Unadj.) | Rs | 17.5 | 44.4 | - | |
| Cash flow per share (Unadj.) | Rs | 26.0 | 350.6 | - | |
| Dividends per share (Unadj.) | Rs | 4.00 | 0 | - | |
| Dividend yield (eoy) | % | 1.0 | 0 | - | |
| Book value per share (Unadj.) | Rs | 188.7 | 1,769.3 | - | |
| Shares outstanding (eoy) | m | 2,399.26 | 514.50 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 2.9 | 1.7 | 173.3% | |
| Avg P/E ratio | x | 22.9 | 62.0 | 36.9% | |
| P/CF ratio (eoy) | x | 15.4 | 7.9 | 195.6% | |
| Price / Book Value ratio | x | 2.1 | 1.6 | 136.0% | |
| Dividend payout | % | 22.9 | 0 | - | |
| Avg Mkt Cap | Rs m | 958,864 | 1,417,614 | 67.6% | |
| No. of employees | `000 | 17.8 | 35.0 | 50.7% | |
| Total wages/salary | Rs m | 63,624 | 0 | - | |
| Avg. sales/employee | Rs Th | 18,490.6 | 24,041.6 | 76.9% | |
| Avg. wages/employee | Rs Th | 3,582.6 | 0 | - | |
| Avg. net profit/employee | Rs Th | 2,357.6 | 652.8 | 361.1% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 328,375 | 841,456 | 39.0% | |
| Other income | Rs m | 6,360 | 0 | - | |
| Total revenues | Rs m | 334,735 | 841,456 | 39.8% | |
| Gross profit | Rs m | 69,898 | 217,738 | 32.1% | |
| Depreciation | Rs m | 20,528 | 157,554 | 13.0% | |
| Interest | Rs m | 3,027 | 40,471 | 7.5% | |
| Profit before tax | Rs m | 52,702 | 19,713 | 267.3% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -2,606 | 0 | - | |
| Tax | Rs m | 8,228 | -3,136 | -262.4% | |
| Profit after tax | Rs m | 41,868 | 22,849 | 183.2% | |
| Gross profit margin | % | 21.3 | 25.9 | 82.3% | |
| Effective tax rate | % | 15.6 | -15.9 | -98.1% | |
| Net profit margin | % | 12.8 | 2.7 | 469.5% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 316,542 | 469,868 | 67.4% | |
| Current liabilities | Rs m | 157,064 | 342,586 | 45.8% | |
| Net working cap to sales | % | 48.6 | 15.1 | 321.1% | |
| Current ratio | x | 2.0 | 1.4 | 146.9% | |
| Inventory Days | Days | 88 | 84 | 104.7% | |
| Debtors Days | Days | 105 | 93 | 112.2% | |
| Net fixed assets | Rs m | 243,102 | 163,229 | 148.9% | |
| Share capital | Rs m | 2,399 | 448 | 535.5% | |
| Net worth | Rs m | 452,645 | 910,302 | 49.7% | |
| Long term debt | Rs m | 20,289 | 982,508 | 2.1% | |
| Total assets | Rs m | 682,525 | 2,441,784 | 28.0% | |
| Interest coverage | x | 18.4 | 1.5 | 1,237.9% | |
| Debt to equity ratio | x | 0 | 1.1 | 4.2% | |
| Sales to assets ratio | x | 0.5 | 0.3 | 139.6% | |
| Return on assets | % | 6.6 | 2.6 | 253.7% | |
| Return on equity | % | 9.2 | 2.5 | 368.5% | |
| Return on capital | % | 11.2 | 3.2 | 353.3% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 65,548 | 174,855 | 37.5% | |
| From Investments | Rs m | -25,888 | -90,381 | 28.6% | |
| From Financial Activity | Rs m | -57,151 | -81,458 | 70.2% | |
| Net Cashflow | Rs m | -13,857 | 1,449 | -956.6% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 74.67 Rs / USD
Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare SUN PHARMA With: J.B.CHEMICALS ELDER PHARMA AUROBINDO PHARMA GSK PHARMA NATCO PHARMA
Today's Market
Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.
Related Views On News
SUN PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 87.4% (Quarterly Result Update)
Feb 1, 2021 | Updated on Feb 1, 2021For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2019-20 Annual Report Analysis (Annual Result Update)
Dec 11, 2020 | Updated on Dec 11, 2020Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
SUN PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 66.9% (Quarterly Result Update)
Nov 6, 2020 | Updated on Nov 6, 2020For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Aug 6, 2019 | Updated on Aug 6, 2019Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
More Views on NewsMost Popular
A Critical Update on the Market (Fast Profits Daily)
Mar 30, 2021In this video, I'll tell you why I am recommending caution in the market at this time.
My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)
Mar 31, 2021A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
My Stock Trading Strategy (Fast Profits Daily)
Mar 31, 2021In this video I'll show you exactly how I go about picking stocks for trading.
What You Need to Find Hundred Baggers (Profit Hunter)
Mar 30, 2021100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More
